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Stem Cell Research (2015) 14, 243–257REVIEWStem cell treatment of degenerative
eye disease☆Ben Meada,b,⁎, Martin Berrya, Ann Logana, Robert A.H. Scott a,
Wendy Leadbeater a,1, Ben A. Schevenb,1a Neurotrauma Research Group, Neurobiology Section, School of Clinical and Experimental Medicine,
University of Birmingham, B15 2TT, UK
b School of Dentistry, University of Birmingham, B4 6NN, UKReceived 24 September 2014; received in revised form 12 February 2015; accepted 14 February 2015Abstract
Stem cell therapies are being explored extensively as treatments for degenerative eye disease, either for replacing lost neurons,
restoring neural circuits or, based on more recent evidence, as paracrine-mediated therapies in which stem cell-derived trophic
factors protect compromised endogenous retinal neurons from death and induce the growth of new connections. Retinal
progenitor phenotypes induced from embryonic stem cells/induced pluripotent stem cells (ESCs/iPSCs) and endogenous retinal
stem cells may replace lost photoreceptors and retinal pigment epithelial (RPE) cells and restore vision in the diseased eye,
whereas treatment of injured retinal ganglion cells (RGCs) has so far been reliant on mesenchymal stem cells (MSC). Here, we
review the properties of non-retinal-derived adult stem cells, in particular neural stem cells (NSCs), MSC derived from bone
marrow (BMSC), adipose tissues (ADSC) and dental pulp (DPSC), together with ESC/iPSC and discuss and compare their potential
advantages as therapies designed to provide trophic support, repair and replacement of retinal neurons, RPE and glia in
degenerative retinal diseases. We conclude that ESCs/iPSCs have the potential to replace lost retinal cells, whereas MSC may be a
useful source of paracrine factors that protect RGC and stimulate regeneration of their axons in the optic nerve in degenerate eye
disease. NSC may have potential as both a source of replacement cells and also as mediators of paracrine treatment.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Abbreviations: ADSCs, adipose-derived stem cells; AMD, age-related macular degeneration; BDNF, brain-derived neurotrophic factor;
BMSCs, bone marrow-derived stem cells; CNS, central nervous system; CNTF, ciliary neurotrophic factor; DPSC, dental pulp stem cells; EGF,
epidermal growth factor; ERG, electroretinogram; ESCs, embryonic stem cells; FGF, fibroblast growth factor; GDNF, glial cell line-derived
neurotrophic factor; GFAP, glial fibrillary acidic protein; iPSCs, induced pluripotent stem cells; ivit, intravitreal; MSC, mesenchymal stem
cells; mTOR, mammalian target of rapamycin; NGF, nerve growth factor; NSCs, neural stem cells; NT-3, neurotrophin-3; NTFs, neurotrophic
factors; ONL, outer nuclear layer; RCS, Royal College of Surgeons rats; RGC, retinal ganglion cell; RPE, retinal pigment epithelial cells; SCI,
spinal cord injury; TBI, traumatic brain injury; TrK, tropomyosin related kinase; VEGF, vascular endothelial growth factor.
☆ Grant information: Rosetrees Trust and BBSRC studentship, grant number BB/F017553/1.
⁎ Corresponding author at: Neurotrauma Research Group, Neurobiology Section, School of Clinical and Experimental Medicine, University of
Birmingham, B15 2TT, UK.
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The loss of retinal neurons, their connections and supporting
glia in ocular degenerative diseases causes permanent blind-
ness, principally because lost photoreceptors and retinal
ganglion cells (RGCs) are not replaced and RGC axons fail to
regenerate (Berry et al., 2008). Clinically, there are neither
neuroprotective nor axogenic therapies available that restore
lost visual system connectivity in retinal degenerative disease
and translatable techniques for the replacement of lost RGC
and photoreceptors are in their infancy. The retina is classified
as central nervous system (CNS) tissue and the characteristics of
its regenerative response are shared by other CNS tissues,
including the brain and spinal cord.
Stem cell treatments developed as therapies for retinal
degeneration fall into two broad categories: stem cells from
(1), sources exogenous to the retina including mesenchymal
stem cells (MSC) neural stem cells (NSCs) and embryonic/
induced pluripotent stem cells (ESCs/iPSCs); and (2), endoge-
nous retinal stem cells such as Müller glia (Ooto et al., 2004;
Reichenbach and Bringmann, 2013), ciliary epithelia-derived
stemcells (Ahmad et al., 2000; Tropepe et al., 2000) and retinal
pigment epithelial (RPE) stem cells.
Potential non-retinal-derived adult stem cell based strate-
gies being developed to treat retinal degeneration include NSC
(McGill et al., 2012; Lu et al., 2013) and MSC derived from
either bone marrow (BMSC) (Yu et al., 2006; Johnson et al.,
2010; Levkovitch-Verbin et al., 2010), adipose tissues (ADSC)
(Tsuruma et al., 2014) or dental pulp (DPSC) (Mead et al.,
2013). MSC predominantly provide trophic support for the
neuroprotection and axon regeneration of damaged retinal
cells either directly through the secretion of neurotrophic
factors (NTFs) (Johnson et al., 2010; Johnson et al., 2013; Meadet al., 2013) or possibly indirectly after stimulation of endo-
genous retinal cells (Lee et al., 2012) which, when activated,
could provide additional paracrine support and/or effect cell
replacement. There is no evidence that ESCs/iPSCs provide
substantial paracrine support, but they do seem to be able to
replace degenerating photoreceptors and RPE cells (Carr et al.,
2009b; Lamba et al., 2009). NSCs directly differentiate into
neural and glial phenotypes after transplantation into spinal
cord injury (SCI) and traumatic brain injury (TBI) sites (Jeong et
al., 2003; Lu et al., 2012). They also secrete trophic factors (Lu
et al., 2003) and, although limited work has been performed in
the eye with NSC, may have potential for both the neuropro-
tection and replacement of retinal neurons, including RGC. The
differential efficiency of NSC/MSC/ESC/iPSC to perform these
disparate tasks is the key to identifying the phenotype most
fitted to provide the optimal safe therapy for retinal disease.
Of the endogenous retinal stem cells, Müller glia have been
induced to dedifferentiate into retinal progenitors which can
then transform into multiple retinal phenotypes including
photoreceptors in the photoreceptor-damaged eye (Osakada
et al., 2007; Liu et al., 2013). Ciliary epithelial-derived stem
cells are self-renewing, multipotential retinal progenitor
cells found in the pigmented ciliary epithelium of the retina
(Xu et al., 2007), some of which differentiate in vitro into
rhodopsin+ photoreceptors (Ballios et al., 2012; Clarke et al.,
2012; Del Debbio et al., 2013). The RPE layer generates new
retina in some animals (Fischer, 2005) and, in humans, contains
a small population of stem cells that can mature into new RPE
cells as well as cells with a neuronal phenotype (Salero et al.,
2012).Whilstmanipulation (Yu et al., 2014) and transplantation
(Chacko et al., 2003; Canola et al., 2007) of endogenous retinal
stem cells have the potential to treat retinal degeneration,
their mechanism of action is largely restricted to RPE and
Table 1 Current clinical trials that test the safety and efficacy of stem cell transplantation for the treatment of degenerative eye disease. Further details found at www.
clinicaltrials.gov.
Treatment Disease Stage No. of
subjects
Estimated
completion
date
Outcome Clinicaltrials.gov
identifier
Intravitreal BMSC AMD, glaucoma Recruiting participants 300 Aug 2017 Visual acuity, visual field NCT01920867
Intravitreal BMSC AMD, diabetic retinopathy,
retinitis pigmentosa
Recruiting participants
(Park et al., 2015)
15 Dec 2015 Incidence and severity of adverse events NCT01736059
Intravitreal BMSC Retinitis pigmentosa Recruiting participants 10 Aug 2016 Visual acuity, quality of life, visual field,
ERG, VEP, colour vision, contrast sensitivity
NCT02280135
Intravitreal BMSC Glaucoma Recruiting participants 10 Dec 2016 Incidence and severity of adverse events,
visual acuity, visual field, OCT, ERG
NCT02330978
Intravitreal BMSC Retinitis pigmentosa Completed (Siqueira et al.,
2011)
50 June 2013 Visual acuity NCT01560715
Intravitreal BMSC Ischemic retinopathy Recruiting participants 30 Jan 2014 Size of foveal avascular zone NCT01518842
Intravitreal BMSC AMD Recruiting participants 1 June 2015 Incidence and severity of adverse events NCT02016508
Intravitreal BMSC AMD, Stargardt's macular
dystrophy
Recruiting participants 10 Dec 2015 Visual acuity NCT01518127
Intravenous bone marrow
mononuclear cells
Optic atrophy Recruiting participants 24 July 2016 Visual function, reduction in optic nerve
degeneration
NCT01834079
Intravitreal AMSC Dry AMD Recruiting participants 100 June 2016 Incidence and severity of adverse events,
visual acuity
NCT02024269
Subretinal ESC-derived RPE Dry AMD Recruiting participants 12 April 2016 Visual acuity, ERG, OCT NCT01674829
Subretinal ESC-derived RPE AMD Pre-recruitment 10 June 2017 Incidence and severity of adverse events,
visual acuity
NCT01691261
Subretinal ESC-derived RPE Stargardt's macular
dystrophy
Recruiting participants
(Schwartz et al., 2012;
Schwartz et al., 2014)
16 Dec 2014 Incidence and severity of adverse events NCT01345006
Subretinal ESC-derived RPE Dry AMD Recruiting participants
Schwartz et al. (2014)
16 Dec 2014 Incidence and severity of adverse events NCT01344993
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246 B. Mead et al.photoreceptor replacement with RGC replacement proving
more refractory to such strategies.
There are currently many clinical trials ongoing which aim
to test the safety and efficacy of stem cell transplantation in
the eye (Table 1). This review focuses on the potential of non
retinal-derived stem cells, in particular NSC, BMSC, ADSC, DPSC
and ESC/iPSC for the treatment of traumatic and degenerative
eye disease and, where relevant, inter-relates some findings
from stem cell research in the spinal cord and brain. Much
overlap exists regarding the mechanisms and efficacy of ESC
and iPSC and is therefore discussed together, readers are
directed towards the following reviews for specific discussion
on ESC (Reynolds and Lamba, 2013) and iPSC (Wright et al.,
2014) for the treatment of the retina. Readers are also referred
to the following articles discussing treatments using MSC not
discussed in this review, such as umbilical blood-derived MSC
(Zwart et al., 2009; Chen et al., 2013), as well as endogenous
retinal stem cells (Yu et al., 2014).Ntf-mediated effects of stem cells
Retinal cell degeneration
The extensive literature on NTF-mediated neuroprotection has
been reviewed by Barde (1989), Sofroniew et al. (2001), Jones
et al. (2001) and Morgan-Warren et al. (2013). After uptake by
axons innervating distant neuronal targets, NTFs are retro-
gradely transported to somata (Dawbarn and Allen, 2003)
where they are neuroprotective. During development, neurons
that fail to innervate their targets are starved of these survival
signals and die by apoptosis (Butowt and von Bartheld, 2003).
Many adult axotomised neurons also atrophy and die after
disconnection from target-derived NTF, but the viability of
neurons with collaterals proximal to the transection site is
protected by a supply of NTF from spared innervated targets
and from local glia (Dougherty et al., 2000; Faulkner et al.,
2004). Since axon collaterals are absent in the optic nerve,
RGCs are exquisitely sensitive to optic nerve damage, so that
approximately 40% die within 7 days (Ahmed et al., 2011) and
90% are lost by 14–21 days (Mey and Thanos, 1993; Berkelaar
et al., 1994). RGC loss detailed above is of relevance to diseases
such as glaucoma and traumatic optic neuropathy.
The failure of adult CNS neurons to regenerate damaged
axons is attributed to suppression of intrinsic axogenic
machinery, the paucity of NTF essential for axon growth cone
advance (Berry et al., 2008) and the presence of axon growth
inhibitory factors (Richardson et al., 1980; Sandvig et al., 2004)
mediating growth cone collapse although the relative
importance of these differing factors is debatable. The
neurotrophins nerve growth factor (NGF), brain-derived neu-
rotrophic factor (BDNF) and neurotrophin-3 (NT-3) phosphory-
late tyrosine residues (Dawbarn and Allen, 2003) after binding
to the tropomyosin related kinase (TrK) receptor and promote
RGC survival and axon growth (Berry et al., 2008) by activating
intracellular signalling pathways (MAPK/PI3K/PKC; Fig. 1),
whilst ciliary neurotrophic factor (CNTF) activates the JAK
pathway after binding to the heterotrimeric gp130 receptor
complex and signal through phosphoinositide-3-kinase (PI3K)/
protein kinase B (Akt) to activate the serine–threonine kinase
mammalian target of rapamycin (mTOR), to promote axogenic
protein synthesis and inhibit glycogen synthase kinase-3β(GSK3β) which, amongst other roles, regulates growth cone
dynamics (Morgan-Warren et al., 2013). Experimental activa-
tion of mTOR signalling in adult mice promotes RGC survival
and axon regeneration after optic nerve transection (Park
et al., 2008; Morgan-Warren et al., 2013). Promoting axon
regeneration is relevant to scenarios in which either the optic
nerve is injured, or RGCs are transplanted into the ganglion cell
layer (Hertz et al., 2014) which subsequently require long
distance regeneration of their axons.
Photoreceptor outer segments are damaged by light and
approximately 10% of the outer segments are recycled by
RPE-mediated phagocytosis each day. The digestion of
internalised phagosomes is not 100% efficient and toxic
lysosomal proteins such as lipofuscin, build up leading to
RPE degeneration (Bharti et al., 2011). The thickening of
the outer limiting membrane and successive reduction in
the supply of diffusible factors to the RPE also contribute to
the degeneration. The subsequent failure in photoreceptor
outer segment phagocytosis by the degenerating RPE is the
primary pathology in age related macular degeneration
(AMD) and retinitis pigmentosa (Bharti et al., 2011).
NTF treatment strategies
Treatments for long term RGC neuroprotection and axon
regeneration are limited and delivery of individual NTF
promotes incomplete and unsustained axon regeneration in
the transected rat optic nerve (Logan et al., 2006) and
spinal cord (Lu et al., 2004b). For example, intravitreal
(ivit) injection of recombinant BDNF and CNTF rescues
axotomised RGC from death for up to 7 days (Mey and Thanos,
1993; Ahmed et al., 2011). Long term trophic support requires
repeated low dose NTF injections (Ko et al., 2000; Ko et al.,
2001) since transient high peak bolus delivery of NTF down-
regulates TrK receptors (Sommerfeld et al., 2000; Chen and
Weber, 2004). Injectable hydrogel formulations composed of
collagen, alginate or chitosan are being developed (Pakulska et
al., 2012) that continuously and slowly release low titres of NTF
in vivo over several weeks. However, drug loading of hydrogels
is limited and thus, for chronic neurodegenerative diseases
like glaucoma, sustained delivery requires repeated hydrogel
implantation, making FDA approval a significant challenge.
Alternative treatments, such as the transplantation of cells with
extended longevity engineered to continuously produce low
levels of specific NTF combinations, remove the need for
repeated injections and overcome the problems with bolus NTF
delivery regimes. For example, ivit transplantation of geneti-
cally engineered fibroblasts that overexpress fibroblast growth
factor-2 (FGF-2), NT-3 and BDNF significantly increases RGC
survival and axon regeneration after optic nerve crush (Logan
et al., 2006).
Stem cells and NTF treatment
Stem cells, transfectedwith ntf genes or induced to secrete NTF
using epidermal growth factor (EGF)/FGF have been grafted
into the retina to treat retinal degeneration e.g. : (1), BMSC
secreting BDNF, glial cell line-derived neurotrophic factor
(GDNF) and neurotrophin-4 are RGC neuroprotective and
improve visual function in cases of traumatic optic neuropathy
(Levkovitch-Verbin et al., 2010), sodium iodate-induced
Figure 1 A schematic diagram showing the proposed mechanism by which MSCs exert their neurotrophic effects on the injured CNS,
including the retina, through secretion of NGF, BDNF, NT-3, CNTF GDNF, VEGF, FGF and PDGF which engage TrK A, B and C, CNTFα,
GFRα, VEGFR, FGFR1 and PDGFR receptors, respectively, leading to the activation of intracellular pathways for axon growth, axon
growth disinhibition and neuroprotection, accounting for the functional recovery seen in animals receiving MSC transplants after
CNS/retinal injury. Some ligand-receptor interactions lead to the activation of the same signalling pathways (abbreviations: BAD,
bcl-2-associated death promoter; Bcl2, B-cell lymphoma 2; FGFR1, fibroblasts growth factor receptor 1; FRS2, fibroblast growth
factor receptor substrate 2; GFRα, GDNF family receptor alpha; Grb2, growth factor receptor-bound protein 2; GSK-3β, glycogen
synthase kinase-3β; IAPS, inhibitor of apoptosis; MAPK, mitogen-activated protein kinase; Mek, mitogen-activated protein kinase;
PDK, phosphoinositide-dependant kinase; PKC, protein kinase C; PLCγ, phospholipase C-gamma).
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ocular hypertension (Harper et al., 2011); (2), NSCs engineered
to secrete CNTF attenuate photoreceptor death in mouse
models of retinitis pigmentosa (Jung et al., 2013); (3), ESC-
derived neural progenitor cells transfected with crystallin-β-b2
promote both RGC and photoreceptor survival (Bohm et al.,
2012); and (4), a glucagon-like peptide-1-secreting cell line
promotes RGC survival after optic nerve crush (Zhang et al.,
2011). Despite possible adverse effects, cell transplantation
“mono-therapies” offer the potential advantages of continuous
secretion ofmultiple NTFs for the duration of the viability of the
transplant. In the eye, BMSC/ADSC/DPSC survive for at least 3 to
5 weeks (Johnson et al., 2010; Levkovitch-Verbin et al., 2010;Haddad-Mashadrizeh et al., 2013; Mead et al., 2013) and ivit
delivery of cell suspensions and transplantation of a retrievable
permeable capsule loaded with stem cells (Zhang et al., 2011)
are also viable options for patients with retinal degenerative
disease (Sieving et al., 2006).Ivit/subretinal stem cell implantation
The fate of transplanted stem cells in the eye remains
undetermined and thus the incidence of immune rejection,
differentiation into unpredicted phenotypes and unbridled
migration within CNS neuropil, together with possible
248 B. Mead et al.oncogenesis, all remain poorly defined. Safeguards against
these outcomes include encapsulation of the stem implant
(Zhang et al., 2011) and genetic modification so that the
cells carry inducible suicide genes, such as viral-derived
thymidine kinase allowing selective destruction of the
transplanted cells when treated with the toxic drug
ganciclovir (Zhang et al., 2011). However, the potential
risks of transplanting stem cells in the eye may have been
exaggerated where cell movement is restrained and immune
reactions muted. For example, after ivit injection, MSC
cluster in the vitreous body (Johnson et al., 2010; Haddad-
Mashadrizeh et al., 2013; Mead et al., 2013, 2013), although
a small number do migrate into the retina they are neither
tumorigenic nor exhibit uncontrolled growth (Johnson et al.,
2010; Mendel et al., 2013; Tzameret et al., 2014). In laser-
induced glaucoma and retinal injury, ivit BMSCs also migrate
into the retina (Singh et al., 2012) where they continue to
proliferate (Wang et al., 2010). After subretinal transplan-
tation, NSCs remain immature for at least 7 months, barely
proliferate and neither exhibit uncontrolled growth nor
oncogenesis, but they do migrate from the injection site
within the subretinal space (McGill et al., 2012; Lu et al., 2013).
By contrast, after ivit transplantation, NSCs either attach to the
retina and lens where they remain (Jung et al., 2013), or
integrate into the inner retinal layers (Grozdanic et al., 2006).
ESC-derived RPE cells transplanted into the subretinal space
of Royal College of Surgeon (RCS) rats (which spontaneously
undergo RPE and subsequent photoreceptor degeneration)
survive for over 200 days, preserve visual function with
evidence of neither teratoma formation (Lu et al., 2009) nor
proliferation (Vugler et al., 2008). Reactive retinal gliosis
rather than penetration of the internal limiting membrane
is proposed as a major limitation to retinal integration of
ESC after ivit implantation (Banin et al., 2006); whilst after
subretinal grafting cell migration is more extensive (Banin
et al., 2006; Lamba et al., 2009) yet still hindered by the
outer limiting membrane (West et al., 2008).
Immunological acceptance of stem cells
transplanted into the eye
The vitreous cavity, like the anterior chamber of the eye, is an
immunoprivileged environment (Jiang and Streilein, 1991) and
thus amenable to cell transplantation. MSC fail to trigger an
immune response when challenged with allogeneic lympho-
cytes and MSC-derived factors inhibit the proliferation of
immunological cells (Kode et al., 2009; Singer and Caplan,
2011). These immunosuppressive/immunomodulatory actions
of BMSC have led to Phase I (Le Blanc et al., 2004), Phase II
(Le Blanc et al., 2008) and Phase III (Martin et al., 2010)
clinical trials for the treatment of steroid refractory graft-
versus-host disease. ADSCs suppress the immune system with
the same efficacy as BMSC in vitro (Puissant et al., 2005) and
increase the survival rate of transplants in animal models
of graft versus host disease (Yañez et al., 2006), whereas
DPSC are as efficient as BMSC in the suppression of T cell
proliferation in vitro (Pierdomenico et al., 2005). Thus,
the failure of the host to launch immune reactions after
ivit/subretinal implantation of MSC is probably explained
by both the immune privileged status of these sites and
the immunosuppressive properties of MSC. For example,immunosuppression is not required and adverse effects
are not recorded after human BMSC (Johnson et al., 2010;
Levkovitch-Verbin et al., 2010; Tzameret et al., 2014)/
ADSC (Haddad-Mashadrizeh et al., 2013)/rodent DPSC
(Mead et al., 2013) transplantation into the eye. Equally,
although not immunosuppressive, iPSC derived from the
somatic cells of the recipient carry the same histocom-
patibility antigens and do not require immunosuppression
after transplantation. By contrast, ESCs/NSCs require immu-
nosuppression when transplanted into the CNS in animals and,
since autologous transplantation is not possible, immunosup-
pression is required in NSC-based treatment (Cummings et al.,
2005; Lu et al., 2012; Schwartz et al., 2012; Lu et al., 2013).
Indeed, NSC transplantation into the subretinal space requires
daily immunosuppressive treatment with cyclosporine A
and dexamethasone (McGill et al., 2012). When transplanted
into the vitreous without immunosuppression, NSCs are
detected in just 50% of transplanted eyes 32 days after
grafting (Grozdanic et al., 2006) suggesting that the immuno-
privileged environment of the vitreous does not sustain
survival of NSC. ESC-derived RPE cells are one of the first
ESC based therapies to be used in humans and early reports of
subretinal transplantation as a treatment for AMD confirm
their safety, although patients require immunosuppression
throughout (Schwartz et al., 2012).
Therapeutic potential of stem cell
replacement therapies
NSC
NSC transplantation is beneficial to recovery in a range of CNS
injury models, including retinal degeneration (McGill et al.,
2012), SCI (Lu et al., 2003; Abematsu et al., 2010; Lu et al.,
2012), stroke (Jeong et al., 2003) and TBI (Riess et al., 2002),
although in many cases, it is unclear if the improved functional
recovery observed is attributable to replacement of lost cells
and/or trophic support of surviving cells.
For example, when transplanted into injured CNS sites such
as those of SCI and TBI, NSCs differentiate into neurons and
glia (Riess et al., 2002; Jeong et al., 2003; Cummings et al.,
2005; Martino and Pluchino, 2006; Abematsu et al., 2010;
Lu et al., 2012), replacing lost cells and providing trophic
support for damaged endogenous neurons (Lu et al., 2003).
NSC differentiation is greatly enhanced by containment in a
matrix loaded with multiple growth factors (Lu et al., 2012)
and treatment with specific differentiation factors (Cao et al.,
2001). In these instances, functional recovery is attributed
to the generation of new NSC-derived neurons that directly
integrate into the host neuronal circuitry (Martino and
Pluchino, 2006; Abematsu et al., 2010) and not to the
paracrine mediated axon regeneration and neuroprotection
characteristic of MSC treatment.
Despite recent success with NSC in other CNS injury
models, few studies have shown the same effect in the eye.
In rats, ivit transplantation of NSC after optic neuropathy
induced by elevated intraocular pressure does not improve
retinal function, despite neuronal differentiation and inte-
gration into inner retinal layers (Grozdanic et al., 2006). A
similar study using mice lacking RGC (induced by removal of
the superior colliculus) showed that NSCs integrate into the
249Stem cell treatment of degenerative eye diseaseretina but sparsely form βIII-tubulin+ mature neurons and
do not form functional RGC (Mellough et al., 2004). Re-
innervation of central targets by the axons of replacement
RGC is not yet possible and there is no evidence to suggest
that regeneration of stem cell-derived RGC axons along
the optic nerve occurs. Indeed, more success has been seen
in RCS rats in which the retinal degeneration is of the
photoreceptors rather than the RGC (McGill et al., 2012).
Subretinal transplantation of NSC protects photoreceptors from
death in RCS rats (McGill et al., 2012) by their phagocytosis of
photoreceptor outer segments, a role usually restricted to RPE
cells which, in RCS rats, are dysfunctional (Cuenca et al., 2013).
Although a paracrine effect (i.e. secretion of NTF) has been
suggested to mediate the effects of NSC in the retina, studies
have only demonstrated this when NSCs are genetically
modified (e.g. to secrete CNTF (Jung et al., 2013)). The
limited number of studies published on NSC in the eye suggests
that this stem cell is currently not useful for replacement of
RGC, however, functional replacement of photoreceptors
by NSC is more plausible because of their short synaptic
distances. Despite this, integration of NSC into the outer
nuclear layer (ONL) is not followed by differentiation into
calbindin+/rhodopsin+ mature photoreceptors (Nishida et al.,
2000) and subretinal transplanted NSCs protect, rather than
replace photoreceptors (McGill et al., 2012; Jung et al., 2013).
BMSC
In vitro neuronal differentiation and neuritogenesis of BMSC are
probably artefacts resulting from cell shrinkage and toxicity
yielding morphologies characteristic of neurons (Lu et al.,
2004a; Neuhuber et al., 2004). Undifferentiated BMSCs co-
express many functional ion channels (Li et al., 2006) as well as
mature neuronal and glial markers, such as βIII-tubulin and
GFAP, respectively (Karaoz et al., 2011; Tamaki et al., 2012)
making successful phenotypic differentiation difficult to detect.
The ability of BMSC to differentiate into neurons and replace
those lost from injury is rarely reported in vivo (Vallières and
Sawchenko, 2003). Their transplantation into the injury site
after SCI promotes functional recovery without any evidence
of neuronal replacement by BMSC differentiation (Kang et al.,
2012).
In the eye, transplantation of BMSC into the vitreous after
experimentally-induced glaucoma and optic nerve transection
shows no evidence of their differentiation into mature retinal
cells, despite some integration into the retina (Yu et al., 2006;
Johnson et al., 2010; Levkovitch-Verbin et al., 2010). After
transplantation into the subretinal space in RCS rats and
mouse models of retinitis pigmentosa, BMSCs sparsely differ-
entiate into cells with neuron and glia characteristics, but not
mature photoreceptors or RPE cells (Zhang and Wang, 2010;
Tzameret et al., 2014) and a protective effect on endogenous
photoreceptors and RPE cells is observed (Arnhold et al., 2007;
Lu et al., 2010).
ADSC
There is conflicting evidence for the differentiation of ADSC into
neurons in vivo and in vitro (Anghileri et al., 2008; Ye et al.,
2010). BDNF/retinoic acid treatments induce the differentia-
tion of ADSC into functional neurons, confirmed by patch clampanalysis and the expression of phenotypic neuronal markers
(Anghileri et al., 2008). The ADSC-derived neuronal phenotypes
demonstrated in this and other studies (Ye et al., 2010)
is only transient with de-differentiation occurring after
withdrawal of the differentiation-inducing medium (Ye
et al., 2010), explaining why ADSC-derived neurons are
rarely seen in vivo after transplantation in animal models of
stroke (Kang et al., 2003). Both studies (Kang et al., 2003; Ye
et al., 2010) concluded that cerebrospinal fluid and CNS
neuropil do not sustain neuronal differentiation of ADSC. By
contrast, ADSCs pre-differentiated into NG2+/S100+ glia
survive for up to 8 weeks after transplantation into rodent
SCI sites (Arboleda et al., 2011) and thus, like other MSC,
probably differentiate preferentially into glia in vivo (Cao
et al., 2001; Cho et al., 2009; Leong et al., 2012).
ADSCs survive for up to 90 days in the vitreous cavity
after transplantation although their fate has not been
studied (Haddad-Mashadrizeh et al., 2013). Interestingly,
ADSC transplanted into the vitreous cavity of mouse models
of diabetic retinopathy preferentially differentiate into
pericytes, associating with and conserving the retinal
vasculature, suggesting a unique role for ADSC in treating
diabetic retinopathy (Mendel et al., 2013). The failure of
ADSC to integrate into the retinal layers diminishes their
potential for RGC and photoreceptor replacement (Mendel
et al., 2013).
DPSC
DPSC differentiate into functionally active neurons in vitro
(Arthur et al., 2008; Kiraly et al., 2009) and,when transplanted,
integrate and survive in injured rat brain tissue for at least
4 weeks (Kiraly et al., 2011; Fang et al., 2013). Other studies
demonstrate that, although DPSC-derived neurons express
neuronal phenotypic markers, they neither generate action
potentials nor form functional neuronal networks (Aanismaa
et al., 2012). Like BMSC, they constitutively express mature
neuronal and glial phenotypic markers even in an undifferen-
tiated state and this may explain the contradictions in the
literature if these characteristics are taken as a read out of
successful differentiation (Karaoz et al., 2011; Tamaki et al.,
2012). In vivo, transplantation of DPSC into rat SCI lesion sites
leads to functional recovery yet only glial, not neuronal,
differentiation is observed (Sakai et al., 2012), suggesting that
differentiation of DPSC into neurons is possible in vitro but
currently has not yet been realised in vivo. After transplantation
into the vitreous, DPSC do not differentiate into neurons and fail
to integrate into the retina (Mead et al., 2013), limiting their
potential as a cell replacement therapy.
ESC/iPSC
The greatest potential for cell replacement has been seen
with ESC/iPSC, which can be successfully predifferentiated
prior to transplantation in the eye, with the most success
demonstrated in RPE/photoreceptor replacement for AMD
(Fig. 2).
ESC can be directed towards a retinal phenotype with
developmental induction signals including bone morphoge-
netic protein (BMP) antagonists (Lamb et al., 1993), Wnt
inhibition (Wilson and Houart, 2004) and insulin-like growth
Figure 2 A diagram showing the proposed way in which ESC/iPSC-derived RPE and photoreceptors can be used to treat AMD/
photoreceptor degeneration. The left panel shows a rat retina immunohistochemically stained for cone annexin (cone photoreceptor
marker; green), Brn3a (RGC marker; red) and DAPI (nuclear marker; blue) with the individual layers labelled (scale bar: 100 μm). On the
right, RPE is represented together with photoreceptor loss in AMD and the potential for cell replacement in preventing visual decline and
restoring vision.
250 B. Mead et al.factor (IGF) treatment (Pera et al., 2001). Accordingly, 30%
of ESC/iPSC differentiate into retinal progenitors (Ikeda
et al., 2005), a number that increases to 80% for both ESC
(Lamba et al., 2006) and iPSC (Tucker et al., 2011) by
incorporating BMP/Wnt inhibition with IGF and FGF treat-
ments. These ESC/iPSC-derived retinal progenitors success-
fully mature into photoreceptors as well as RPE cells and
integrate into retinal explants after co-culture with adult
retina/retinal neurons (Osakada et al., 2008) or after the
addition of a cocktail of small molecules (Osakada et al.,
2009b). Comparisons of the gene expression profiles of ESC-
derived retinal cells with primary developing foetal retinal
cells using microarray analysis show them to be highly
conserved between the two cell sources throughout devel-
opment (Lamba and Reh, 2011).
ESC-derived retinal progenitors, primed to form neuronal
retina rather than RPE using FGF, successfully differentiate
into photoreceptors (Hambright et al., 2012), integrate into
the ONL (Lamba et al., 2009) and survive for over 3 months
in the subretinal space of non-immunosuppressed mice
with an intact blood–retinal barrier, with integration more
significant when the retina is injured (Hambright et al.,
2012). iPSC-derived photoreceptors transplanted into the
subretinal space integrate into the ONL and increase retinal
function as determined by electroretinogram (ERG) (Tuckeret al., 2011). Transplantation of ESC-derived photoreceptors
into the vitreous of newborn mice leads to their correct
topographic integration into all the layers of the retina,
i.e. ESC-derived photoreceptors move to the ONL, whereas
ESC-derived amacrine cells and RGC-like cells migrate to the
inner nuclear layer/ganglion cell layer (Lamba et al., 2009;
Reynolds and Lamba, 2013). However, integration is only
possible up to 48 h after birth, corroborating reports that in
adult rats, ivit ESC-derived cells fail to integrate into the
retina (Banin et al., 2006).
Both mouse (Eiraku et al., 2011) and human (Nakano et al.,
2012) ESC can be induced to form a complete topographically
organized retina, including the RPE. Developing photorecep-
tors, isolated from ESC-derived ex vivo retina, integrate after
transplantation into mouse models of retinal degeneration
(Gonzalez-Cordero et al., 2013). These findings have been
replicated using iPSC showing the formation of a synaptically
connected stratified retina (Phillips et al., 2012).
ESC/iPSC can be induced to predominantly differentiate
into RPE cells using similar protocols as above, but with the
omission/antagonism of FGF to bias the generation of RPE
cells over neural retina (Meyer et al., 2009; Osakada et al.,
2009a). These ESC/iPSC-derived RPE cells phagocytise photo-
receptor outer segments (Carr et al., 2009a) and preserve
retinal function in the RCS rats (Vugler et al., 2008; Carr et al.,
Table 2 NTF known to be secreted by NSC, BMSC, ADSC and DPSC. NTF secretion by ESC/iPSC is currently unreported.
Stem cells Neurotrophic factor secretion profile
NSC NGF, BDNF, NT-3, GDNF (Lu et al., 2003); (Gu et al., 2012); (He et al., 2012)
BMSC NGF, BDNF, NT-3, NT-4/5, CNTF, GDNF, PDGF (Dormady et al., 2001); (Chen et al., 2005); (Wilkins et al., 2009);
(Ghorbanian et al., 2012); (Sakai et al., 2012); (Johnson et al., 2013); (Mead et al., 2013, 2014)
ADSC NGF, BDNF, NT-3, GDNF, VEGF, Progranulin, SPARC (Kalbermatten et al., 2011); (Sugitani et al., 2013);
(Zhou et al., 2013); (Tsuruma et al., 2014); (Mead et al., 2014)
DPSC NGF, BDNF, NT-3, CNTF, GDNF, VEGF, FGF-2 (Nosrat et al., 1997, 2001); (Huang et al., 2008); (Gale et al., 2011);
(Sakai et al., 2012); (Mead et al., 2013, 2014)
251Stem cell treatment of degenerative eye disease2009b). A study comparing adult human ESC-derived RPE with
foetal human RPE demonstrated a strong correlation in their
gene expression profiles. However, iPSC-derived RPE have a
distinct gene expression profile, indicating potential differ-
ences between ESC-derived retinal cells and iPSC-derived
retinal cells (Liao et al., 2010).
Subretinal transplantation of ESC/iPSC-derived RPE in
cases of AMD requires approximately 60,000 cells (Bharti et
al., 2011) to restore RPE-mediated recycling of photorecep-
tor outer segments. In contrast to photoreceptor replace-
ment, in this instance significant migration, integration and
synaptogenesis is not required to achieve functional effica-
cy. Its effectiveness is already proven by the fact that
current surgical intervention relies on the same principles
i.e. translocating the macula to an adjacent, healthy portion
of RPE (da Cruz et al., 2007). These attributes have led to
the first clinical trial transplanting ESC-derived RPE cells in
patients with AMD (Schwartz et al., 2012).
ESCs/iPSCs are able to differentiate into RGC and,
during the formation of ESC-/iPSC-derived retina ex vivo,
RGCs are the first cells to develop which mimic normal
retinal development (Eiraku et al., 2011; Nakano et al.,
2012; Phillips et al., 2012). The yield of RGC is enhanced by
transfection of the stem cells with genes regulating RGC
development, namely math5 and sox4 (Jiang et al., 2013).
Similar to ESC/iPSC-derived photoreceptors integrating
into the ONL, transplanted adult rat RGCs integrate and
survive in the ganglion cell layer (Hertz et al., 2014) but,
unlike photoreceptors, the long distances over which RGC
axons must regenerate to re-innervate central targets is
unachievable (Sun et al., 2011).
Therapeutic potential of stem cell trophic
support (Fig. 1; Table 2)
NSC
When transplanted into SCI lesion sites, NSCs increase the
expression of NGF, BDNF, NT-3 and GDNF within the lesion
site (Gu et al., 2012; He et al., 2012) and promote axonal
sprouting (Lu et al., 2003). However, the trophic support
provided by undifferentiated NSC only minimally restores
function compared to when they are induced to differenti-
ate down a neuronal lineage before or after transplantation
into SCI sites (Cao et al., 2001; Abematsu et al., 2010; Gu
et al., 2012; He et al., 2012). In the eye, as stated above,
ivit NSCs transplanted into the vitreous fail to improve
function in models of elevated intraocular pressure-inducedRGC loss (Grozdanic et al., 2006) and axotomy (Flachsbarth
et al., 2014) and only show neuroprotective efficacy when
transfected to secrete CNTF. However, transplantation
was made four weeks post-injury, so that it cannot be
ruled out that NSC may be able to have a paracrine-
mediated neuroprotective effect on RGC if they were
transplanted at the time of injury when injured RGCs are
most amenable to neuroprotective strategies. Nonetheless,
after subretinal transplantation of NSC into RCS rats, rather
than replaced, photoreceptors are protected against death by
NSC-directed phagocytosis of photoreceptor outer segments
(Cuenca et al., 2013) and induction of CNTF expression by
Müller glia (Lu et al., 2013).BMSC
The neurotrophic secretome of BMSC, which includes NGF,
BDNF, NT-3, NT4/5, CNTF, GDNF and PDGF is widely docu-
mented (Dormady et al., 2001; Chen et al., 2005; Wilkins et al.,
2009; Ghorbanian et al., 2012; Sakai et al., 2012; Johnson et
al., 2013; Mead et al., 2013; Mead et al., 2014) and places them
as a candidate cellular therapy to combat ocular neurodegen-
eration. BMSC-mediated neuroprotection of RGC is reported
to be mediated by PDGF (Johnson et al., 2013), whilst other
studies have shown that BMSC-induced RGC neuroprotection
and axon/neurite growth is mediated by NGF, BDNF and NT-3
(Mead et al., 2013). The importance of BMSC-derived NTF for
retinal neuron survival is confirmed by using TrK and PDGFR
inhibitors which significantly diminish the RGC neuroprotection
and/or neurite growth effects elicited by BMSC (Johnson et al.,
2013; Mead et al., 2013; Mead et al., 2014). The vitreous does
not permit the differentiation of BMSC into neurons (Hill et al.,
2009). Nonetheless, ivit transplanted BMSCs secrete diffusible
NTF, BDNF and NT-3 (Mead et al., 2013), directly protecting
RGC from death in animal models of glaucoma (Yu et al., 2006;
Johnson et al., 2010) and optic nerve transection (Levkovitch-
Verbin et al., 2010; Mead et al., 2013), and can also be
indirectly effective by inducing Müller cell NTF production (Lee
et al., 2012). Interestingly, BMSC also promote the regeneration
of RGC axons after optic nerve crush (Mead et al., 2013),
probably through the same NTF-mediated mechanisms (Berry
et al., 2008). Subretinal and ivit BMSC transplantation in RCS
rats and mouse models of retinitis pigmentosa significantly
improves retinal function by preserving photoreceptor and RPE
cell viability (Arnhold et al., 2007; Lu et al., 2010; Tzameret
et al., 2014) and, although the underlying observations remain
equivocal, a role for the NTF secretome in promoting cell
survival is a likely explanation.
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ADSCs express NGF, BDNF, NT-3, GDNF, VEGF and PDGF
(Kalbermatten et al., 2011; Zhou et al., 2013; Mead et al.,
2014), with titres of BDNF and vascular endothelial growth
factor (VEGF) being significantly higher than those secreted by
BMSC (Zhou et al., 2013). Despite this, ADSCs are relatively
untested in the eye but have efficacy as a paracrine-mediated
therapy in other CNS animal injury models like SCI (Arboleda
et al., 2011; Zhou et al., 2013) and stroke (Kang et al., 2003).
In co-culture, ADSC-derived NTF promote neuroprotection
and neuritogenesis of injured RGC, although the effects are
not as pronounced as those achieved with BMSC/DPSC (Mead
et al., 2014). In a mouse model of light induced photoreceptor
damage, both ivit ADSC and ADSC-conditioned medium
preserve ONL thickness and the amplitude of the a-wave of
the ERG (Sugitani et al., 2013; Tsuruma et al., 2014).
Progranulin, tissue inhibitor of metalloproteinases-1 (TIMP1)
and the secreted protein rich in cysteine (SPARC) are the
active agents produced by ADSC in vitro and, after ivit
transplantation, have similar effects to ivit ADSC/ADSC
conditioned medium. Together, these data suggest that
ADSC have therapeutic potential for neurodegenerative
conditions through NTF production, with many of the active
factors different from those produced by BMSC and DPSC.DPSC
Like other MSCs, DPSCs have an extensive neurotrophic
secretome which includes NGF, BDNF, NT-3, GDNF, VEGF and
PDGF (Nosrat et al., 1997, 2001; Gale et al., 2011; Sakai et al.,
2012; Mead et al., 2013, 2014). Interestingly, DPSCs express
significantly greater amounts of ngf, bdnf and nt-3 mRNA than
BMSC (Sakai et al., 2012) and this is true also for the secreted
proteins NGF, BDNF and NT-3 (Mead et al., 2013). DPSC-
conditioned medium containing the above factors promotes
neurite outgrowth of cortical neurons (Sakai et al., 2012), a
neuroblastoma cell line (Ishizaka et al., 2013) and primary RGC
(Mead et al., 2013, 2014) with significantly greater efficacy
than BMSC and ADSC-conditioned medium. DPSCs transplanted
into mouse hippocampus increase the basal expression levels of
many NTF such as CNTF, VEGF, FGF-2 and NGF (Huang et al.,
2008), although it is unknown if the transplanted DPSCs directly
express these NTFs and/or indirectly promote the expression
of NTFs by neighbouring cells in the surrounding neuropil.
DPSC transplantation into rat SCI lesion sites leads to greater
functional improvement than BMSC transplantation and, with
a lack of observable neuronal differentiation, the evidence
strongly suggests a paracrine-mediated mechanism (Sakai et
al., 2012). Following either ivit transplantation or co-culture
with injured RGC, DPSCs secrete NGF, BDNF and NT-3 and
promote RGC survival and axon/neurite regeneration; effects
which are attenuated by Fc-TrK blockers (Mead et al., 2013,
2014). These neuroprotective/pro-regenerative effects are
significantly greater in DPSC transplanted animals compared
to BMSC transplanted animals and are correlated with a more
favourable neurotrophic secretome by DPSC compared to BMSC
(Mead et al., 2013, 2014). Currently, no evidence exists for
DPSC-mediated protection of photoreceptors whilst further
research into the mechanisms of DPSC-mediated RGC neuro-
protection is required.ESC/iPSC
Unlike MSC, the paracrine potential of ESC/iPSC for treating
the injured retina/CNS is as yet unknown. Addition of TrK
receptor blockers to ESC cultures perturbs their survival,
indicating that neurotrophins are released and active in
an autocrine fashion, but further analysis on the secretome
is required (Pyle et al., 2006). ivit transplantation of ESC-
derived photoreceptors promotes the survival of nearby
endogenous photoreceptors (Meyer et al., 2006). Similarly it
is known that RPE cells secrete VEGF and PEDF, which may
further explain how ESC-derived RPE cells protect photore-
ceptors from death (Strauss, 2005).Conclusions
The use of stem cells has proven potential as a cellular therapy
for retinal degenerative conditions through replacement of lost
cells in the eye and/or the release of growth factors into
damaged neuropil. However, themechanismof action aswell as
the efficacy of the cellular therapy vary between different stem
cells and can contrast greatly with what is seen in other models
of CNS injury. ESCs/iPSCs have shown potential as a source of
retinal cells for replacement of particularly photoreceptors and
RPE, but their possible paracrine action is currently not known.
Although the potential trophic properties are still not fully
understood, NSCs have proven impressive cell replacement
properties in other CNS regions and these faculties may be
enhanced, optimised and refined by pre-treatment with
selected growth/inducible factors leading to their formulation
as an effective cell replacement therapy in the retina. By
contrast the dominant mechanism by which MSCs restore lost
retinal function appears to be paracrine-mediated, which offers
the potential for their use to provide continuous delivery of
multiple growth factors to provide direct trophic support for
neurons in the degenerate retina and to stimulate glia to
indirectly help effect neural repair. The non-invasive, non-
tumorigenic, immunosuppressive and trophic characteristics of
MSC, along with the relatively ease of access from their diverse
adult tissue sources, circumvent moral and ethical dilemmas
and make the autologous and allogeneic intra-ocular implanta-
tion of MSC a promising paracrine-mediated therapy for the
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